Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $57.3 million.

  • Assembly Biosciences' Total Liabilities fell 2283.49% to $57.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.3 million, marking a year-over-year decrease of 2283.49%. This contributed to the annual value of $85.8 million for FY2024, which is 1035.98% down from last year.
  • Latest data reveals that Assembly Biosciences reported Total Liabilities of $57.3 million as of Q3 2025, which was down 2283.49% from $62.7 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Total Liabilities high stood at $95.7 million for Q4 2023, and its period low was $9.9 million during Q3 2023.
  • Over the past 5 years, Assembly Biosciences' median Total Liabilities value was $30.3 million (recorded in 2021), while the average stood at $43.8 million.
  • Per our database at Business Quant, Assembly Biosciences' Total Liabilities crashed by 4965.41% in 2022 and then soared by 64895.61% in 2024.
  • Assembly Biosciences' Total Liabilities (Quarter) stood at $22.1 million in 2021, then fell by 13.56% to $19.1 million in 2022, then skyrocketed by 400.4% to $95.7 million in 2023, then fell by 10.36% to $85.8 million in 2024, then crashed by 33.22% to $57.3 million in 2025.
  • Its Total Liabilities was $57.3 million in Q3 2025, compared to $62.7 million in Q2 2025 and $71.9 million in Q1 2025.